Cetuximab/encorafenibDevelopment of drug resistance and off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1894卷 / 1期

关键词：

D O I：

10.1007/s40278-022-10216-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：103 / 103

相关论文

共 50 条

[1] Cetuximab off-label useAcquired resistance: case report
Reactions Weekly, 2021, 1853 (1) : 123 - 123
[2] AntineoplasticsTreatment failure, drug resistance and off-label use: case report
Reactions Weekly, 2022, 1931 (1) : 85 - 85
[3] ErtapenemAcquired drug resistance following off-label use: case report
Reactions Weekly, 2022, 1909 (1) : 245 - 245
[4] Alectinib/crizotinibAcquired drug resistance and off-label use: case report
Reactions Weekly, 2021, 1856 (1) : 23 - 23
[5] CetuximabAseptic meningitis following off-label use of cetuximab: case report
Reactions Weekly, 2018, 1729 (1) : 72 - 72
[6] Multiple drugsLack of efficacy, drug resistance and off-label use: case report
Reactions Weekly, 2021, 1851 (1) : 242 - 242
[7] Multiple drugsLack of efficacy, drug resistance and off-label use: case report
Reactions Weekly, 2023, 1961 (1) : 290 - 290
[8] Cefepime/piperacillin/tazobactamDevelopment of drug resistance and off-label use: case report
Reactions Weekly, 2023, 1943 (1) : 192 - 192
[9] Multiple drugsLack of efficacy, drug resistance and off-label use: case report
Reactions Weekly, 2021, 1869 (1) : 247 - 247
[10] DexamethasoneInsulin resistance and off-label use: case report
Reactions Weekly, 2022, 1911 (1) : 173 - 173

← 1 2 3 4 5 →